Advertisement

A Multimodal Approach to Melasma

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Cosmetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cestari T.
        • Peruzzo J.
        • Giongo N.
        Definition, incidence, and etiology of melasma in brown skin.
        in: Handog E. Enriquez-Macarayo M. Melasma and vitiligo in brown skin. Springer, New Delhi2017
        • Bak H.
        • Lee H.J.
        • Chang S.E.
        • et al.
        Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma.
        Dermatol Surg. 2009; 35: 1244-1250
        • Handel A.C.
        • Miot L.D.
        • Miot H.A.
        Melasma: a clinical and epidemiological review.
        An Bras Dermatol. 2014; 89: 771-782
        • Ogbechie-Godec O.A.
        • Elbuluk N.
        Melasma: an up-to-date comprehensive review.
        Dermatol Ther. 2017; 7: 305-318
        • Costa A.
        • Moisés T.A.
        • Cordero T.
        • et al.
        Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma.
        An Bras Dermatol. 2010; 85: 613-620
        • Roberts W.E.
        Pollution as a risk factor for the development of melasma and other skin disorders of facial hyperpigmentation - is there a case to be made?.
        J Drugs Dermatol. 2015; 14: 337-341
        • Cestari T.F.
        • Hexsel D.
        • Viegas M.L.
        • et al.
        Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.
        Br J Dermatol. 2006; 156: 13-20
        • Seckin H.Y.
        • Kalkan G.
        • Bas Y.
        • et al.
        Oxidative stress status in patients with melasma.
        Cutan Ocul Toxicol. 2014; 33: 212-217
        • Choubey V.
        • Sarkar R.
        • Garg V.
        • et al.
        Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients.
        Int J Dermatol. 2017; 56: 939-943
        • Babbush K.M.
        • Babbush R.A.
        • Khachemoune A.
        The therapeutic use of antioxidants for Melasma.
        J Drugs Dermatol. 2020; 19: 788-792
        • Babbush K.M.
        • Babbush R.A.
        • Khachemoune A.
        Treatment of melasma: a review of less commonly used antioxidants.
        Int J Dermatol. 2021; 60: 166-173
        • Saeedi M.
        • Eslamifar M.
        • Khezri K.
        Kojic acid applications in cosmetic and pharmaceutical preparations.
        Biomed Pharmacother. 2019; 110: 582-593
        • Berardesca E.
        • Rigoni C.
        • Cantù A.
        • et al.
        Effectiveness of a new cosmetic treatment for melasma.
        J Cosmet Dermatol. 2020; 19: 1684-1690
        • Ennes S.B.P.
        • Paschoalick R.C.
        • Mota De Avelar Alchorne M.
        A double- blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma.
        J Dermatol Treat. 2000; 11: 173-179
        • Westerhof W.
        • Kooyers T.J.
        Hydroquinone and its analogues in dermatology - a potential health risk.
        J Cosmet Dermatol. 2005; 4: 55-59
        • El-Husseiny R.
        • Rakha N.
        • Sallam M.
        Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: a split-face comparative clinical, histopathological, and antera 3D camera study.
        Dermatol Ther. 2020; 33: e14240
        • Atefi N.
        • Dalvand B.
        • Ghassemi M.
        • et al.
        Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma.
        Dermatol Ther. 2017; 7: 417-424
        • Janney M.S.
        • Subramaniyan R.
        • Dabas R.
        • et al.
        A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in Melasma.
        J Cutan Aesthet Surg. 2019; 12: 63-67
        • Kuster Kaminski Arida D.
        • Orso Rebellato P.R.
        • Marioto de Campos G.L.
        • et al.
        Randomized, double-blind, placebo-controlled split-face trial of the efficacy of tranexamic acid by drug delivery through microneedling in the treatment of melasma.
        J Cosmet Dermatol. 2021; 20: 4005-4010
        • Ortonne J.-P.
        Retinoid therapy of pigmentary disorders.
        Dermatol Ther. 2006; 19: 280-288
        • Ghersetich I.
        • Troiano M.
        • Brazzini B.
        • et al.
        Melasma: treatment with 10% tretinoin peeling mask.
        J Cosmet Dermatol. 2010; 9: 117-121
        • Dogra S.
        • Kanwar A.J.
        • Parsad D.
        Adapalene in the treatment of melasma: a preliminary report.
        J Dermatol. 2002; 29: 539-540
        • Kligman A.M.
        • Willis I.
        A new formula for depigmenting human skin.
        Arch Dermatol. 1975; 111: 40-48
        • Kligman L.H.
        • Schwartz E.
        • Lesnik R.H.
        • et al.
        Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect.
        Curr Probl Dermatol. 1993; 21: 79-88
        • Taylor S.C.
        • Torok H.
        • Jones T.
        • et al.
        Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
        Cutis. 2003; 72: 67-72
        • Rendon M.I.
        Utilizing combination therapy to optimize melasma outcomes.
        J Drugs Dermatol. 2004; 3: S27-S34
        • Zaumseil R.P.
        • Graupe K.
        Clinical experience with azelaic acid in melasma.
        J Dermatol Treat. 1994; 4: 237-241
        • Nazzaro-Porro M.
        Azelaic acid.
        J Am Acad Dermatol. 1987; 17: 1033-1041
        • Karrabi M.
        • Mansournia M.A.
        • Sharestanaki E.
        • et al.
        Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study.
        Arch Dermatol Res. 2021; 313: 539-547
        • Nguyen J.
        • Remyn L.
        • Chung I.Y.
        • et al.
        Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial.
        Australas J Dermatol. 2021; 62: e41-e46
        • Karrabi M.
        • David J.
        • Sahebkar M.
        Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: a randomized, double-blind clinical trial study.
        Skin Res Technol. 2021; 27: 24-31
        • Colferai M.M.T.
        • Miquelin G.M.
        • Steiner D.
        Evaluation of oral tranexamic acid in the treatment of melasma.
        J Cosmet Dermatol. 2018; 18: 1-7
        • Del Rosario E.
        • Florez-Pollack S.
        • Zapata Jr., L.
        • et al.
        Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
        J Am Acad Dermatol. 2018; 78: 363-369
        • Wu S.
        • Shi H.
        • Wu H.
        • et al.
        Treatment of melasma with oral administration of tranexamic acid.
        Aesthet Plast Surger. 2012; 36: 964-970
        • Tan A.W.M.
        • Sen P.
        • Chua S.H.
        • et al.
        Oral tranexamic acid lightens refractory melasma.
        Australas J Dermatol. 2017; 58: e105-e108
        • Zhu C.Y.
        • Li Y.
        • Sun Q.N.
        • et al.
        Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study.
        Eur J Dermatol. 2019; 29: 55-58
        • Lajevardi V.
        • Ghayoumi A.
        • Abedini R.
        • et al.
        Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor and analyst-blinded, randomized controlled trial with a short-term follow-up.
        J Cosmet Dermatol. 2017; 16: 235-242
        • Lee H.C.
        • Thng T.G.S.
        • Goh C.L.
        Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis.
        J Am Acad Dermatol. 2016; 75: 385-392
        • Badran A.Y.
        • Ali A.U.
        • Gomaa A.S.
        Efficacy of topical versus intradermal injection of tranexamic acid in egyptian melasma patients: a randomised clinical trial.
        Australas J Dermatol. 2021; 62: e373-e379
        • Sharma R.
        • Mahajan V.K.
        • Mehta K.S.
        • et al.
        Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study.
        Clin Exp Dermatol. 2017; 42: 728-734
        • Sirithanabadeekul P.
        • Dannarongchai A.
        • Suwanchinda A.
        Platelet-rich plasma treatment for melasma: a pilot study.
        J Cosmet Dermatol. 2020; 19: 1321-1327
        • Tuknayat A.
        • Bhalla M.
        • Thami G.P.
        Platelet-rich plasma is a promising therapy for melasma.
        J Cosmet Dermatol. 2021; 20: 2431-2436
        • Deprez P.
        • Deprez P.
        Textbook of chemical peels, second edition: superficial, medium, and deep peels in cosmetic practice.
        in: Series in Cosmetic and laser therapy. CRC Press, an imprint of Taylor and Francis, Boca Raton, FL2016
        • Roberts W.E.
        Chemical peeling in ethnic/dark skin.
        Dermatol Ther. 2004; 17: 196-205
        • Lawrence N.
        • Cox S.E.
        • Brody H.J.
        Treatment of melasma with Jessner's solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination.
        J Am Acad Dermatol. 1997; 36: 589-593
        • Rendon M.I.
        • Berson D.S.
        • Cohen J.L.
        • et al.
        Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing.
        J Clin Aesthet Dermatol. 2010; 3: 32-43
        • Grimes P.E.
        The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups.
        Dermatol Surg. 1999; 25: 18-22
        • Cook K.K.
        • Cook W.R.
        Chemical peeling of non-facial skin using glycolic acid gel augmented with TCA and neutralized based on visual staging.
        Dermatol Surg. 2000; 26: 994-999
        • Erbil H.
        • Sezer E.
        • Taştan B.
        • et al.
        Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma.
        J Dermatol. 2007; 34: 25-30
        • Nanni C.A.
        • Alster T.S.
        Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients.
        Dermatol Surg. 1998; 24: 315-320
        • Bernstein L.
        • Kauvar A.
        • Grossman M.
        • et al.
        The short and long term side effects of carbon dioxide laser resurfacing.
        Dermatol Surg. 1997; 23: 519-525
        • Trelles M.A.
        • Velez M.
        • Gold M.H.
        The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study.
        J Drugs Dermatol. 2010; 9: 315-322
        • Angsuwarangsee S.
        • Polnikorn N.
        Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design.
        Dermatol Surg. 2003; 29: 59-64
        • Wang C.C.
        • Hui C.Y.
        • Sue Y.M.
        • et al.
        Intense pulsed light for the treatment of refractory melasma in Asian persons.
        Dermatol Surg. 2004; 30: 1196-1200
        • Li Y.H.
        • Chen J.Z.S.
        • Wei H.C.
        • et al.
        Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients.
        Dermatol Surg. 2008; 34: 693-701
        • Goldman M.P.
        • Gold M.H.
        • Palm M.D.
        • et al.
        Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
        Dermatol Surg. 2011; 37: 224-233
        • Figueiredo S.L.
        • Trancoso S.S.
        Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma.
        Dermatol Ther. 2012; 25: 477-480
        • Arora P.
        • Sarkar R.
        • Garg V.K.
        • et al.
        Lasers for treatment of melasma and post-inflammatory hyperpigmentation.
        J Cutan Aesthet Surg. 2012; 5: 93-103https://doi.org/10.4103/0974-2077.99436
        • Wattanakrai P.
        • Mornchan R.
        • Eimpunth S.
        Low-fluence q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
        Dermatol Surg. 2010; 36: 76-87
        • Xi Z.
        • Gold M.H.
        • Zhong L.
        • et al.
        Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma.
        Dermatol Surg. 2011; 37: 962-970
        • Hofbauer Parra C.A.
        • Careta M.F.
        • Valente N.Y.S.
        • et al.
        Clinical and histopathologic assessment of facial melasma after low fluence Q-switched neodymium-doped yttrium aluminium garnet laser.
        Dermatol Surg. 2016; 42: 507-512
        • Geronemus R.G.
        Fractional photothermolysis: current and future applications.
        Lasers Surg Med. 2006; 38: 169-176
        • Lee H.M.
        • Haw S.
        • Kim J.K.
        • et al.
        Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in asian skin.
        Dermatol Surg. 2013; 39: 879-888
        • Lee S.M.
        • Kim M.S.
        • Kim Y.J.
        • et al.
        Adverse events of non-ablative fractional laser photothermolysis: a retrospective study of 856 treatments in 362 patients.
        J Dermatol Treat. 2014; 25: 304-307
        • Polnikorn N.
        • Tanghetti E.
        Treatment of refractory melasma in asians with the picosecond alexandrite laser.
        Dermatol Surg. 2020; 46: 1651-1656
        • Ross E.V.
        • Naseef G.
        • Lin C.
        • et al.
        Comparison of responses of tattoos to picosecond and nanosecond Q-switched Neodymium:YAG lasers.
        Arch Dermatol. 1998; 134: 167-171
        • Manuskiatti W.
        • Yan C.
        • Tantrapornpong P.
        • et al.
        A prospective, split-face, randomized study comparing a 755-nm picosecond laser with and without diffractive lens array in the treatment of Melasma in Asians.
        Lasers Surg Med. 2021; 53: 95-103
        • Karadağ Köse Ö.
        • Borlu M.
        Efficacy of the combination of Q-switched Nd:YAG laser and microneedling for melasma.
        J Cosmet Dermatol. 2021; 20: 769-775
        • Jeong S.Y.
        • Bin Shin J.
        • Yeo U.C.
        • et al.
        Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
        Dermatol Surg. 2010; 36: 909-918
        • Hai L.
        • Phuong B.
        • Ha L.
        • et al.
        Dual toning method with the combination of picosecond and microsecond Nd:YAG in refractory melasma unresponsive to picosecond alone.
        J Cutan Aesthet Surg. 2021; 14: 101-106
        • Kang H.
        • Kim J.
        • Goo B.
        The dual toning technique for melasma treatment with the 1064 nm Nd:YAG laser: a preliminary study.
        Laser Ther. 2011; 20: 189-194
        • Yun W.J.
        • Moon H.R.
        • Lee M.W.
        • et al.
        Combination treatment of low-fluence 1,064 nm Q-switched Nd: YAG laser with novel intense pulse light in Korean melasma patients: a prospective, randomized, controlled trial.
        Dermatol Surg. 2014; 40: 842-850
        • Vachiramon V.
        • Sirithanabadeekul P.
        • Sahawatwong S.
        Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma.
        J Eur Acad Dermatol Venereol. 2015; 29: 1339-1346
        • Lindgren A.L.
        • Austin A.H.
        • Welsh K.M.
        The use of tranexamic acid to prevent and treat post-inflammatory hyperpigmentation.
        J Drugs Dermatol. 2021; 20: 344-345
        • Shin J.U.
        • Park J.
        • Oh S.H.
        • et al.
        Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in koreans: a randomized, prospective trial.
        Dermatol Surg. 2013; 39: 435-442
        • Kato H.
        • Araki J.
        • Eto H.
        • et al.
        A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser.
        Dermatol Surg. 2011; 37: 605-610
        • Shah S.D.
        • Aurangabadkar S.J.
        Laser toning in melasma.
        J Cutan Aesthet Surg. 2019; 12: 76-84
        • Aust M.C.
        • Reimers K.
        • Kaplan H.M.
        • et al.
        Percutaneous collagen induction-regeneration in place of cicatrisation?.
        J Plast Reconstr Aesthet Surg. 2011; 64: 97-107
        • Aust M.C.
        • Reimers K.
        • Gohritz A.
        • et al.
        Percutaneous collagen induction. Scarless skin rejuvenation: fact or fiction?.
        Clin Exp Dermatol. 2010; 35: 437-439
        • Falabella A.F.
        • Falanga V.
        Wound healing.
        in: The Biology of the skin. Parthenon, New York, NY2001: 281-299
        • Kaur A.
        • Bhalla M.
        • Pal Thami G.
        • et al.
        Clinical efficacy of topical tranexamic acid with microneedling in Melasma.
        Dermatol Surg. 2020; 46: e96-e101